NO180540B1 - Analogifremgangsmate for fremstilling av terapeutisk aktiv cyklisk amidderivat - Google Patents
Analogifremgangsmate for fremstilling av terapeutisk aktiv cyklisk amidderivatInfo
- Publication number
- NO180540B1 NO180540B1 NO19912252A NO912252A NO180540B1 NO 180540 B1 NO180540 B1 NO 180540B1 NO 19912252 A NO19912252 A NO 19912252A NO 912252 A NO912252 A NO 912252A NO 180540 B1 NO180540 B1 NO 180540B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- cyclic amide
- amide derivative
- preparation
- Prior art date
Links
- 150000003950 cyclic amides Chemical class 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000008569 process Effects 0.000 title claims description 3
- -1 cyclic amide compound Chemical class 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 43
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 1
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940022698 acetylcholinesterase Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000012440 Acetylcholinesterase Human genes 0.000 description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010039966 Senile dementia Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000008191 cerebritis Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- VOBDPVDERULVLB-UHFFFAOYSA-N n-[2-[1-(1,3-dioxolan-2-ylmethyl)piperidin-4-yl]ethyl]-5-methoxy-2-phenylmethoxybenzamide Chemical compound C1CN(CC2OCCO2)CCC1CCNC(=O)C1=CC(OC)=CC=C1OCC1=CC=CC=C1 VOBDPVDERULVLB-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19954229A NO307089B1 (no) | 1990-06-15 | 1995-10-23 | Analogifremgangsmate for fremstilling av terapeutisk aktive cykliske amidderivater |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15713490 | 1990-06-15 |
Publications (5)
| Publication Number | Publication Date |
|---|---|
| NO912252D0 NO912252D0 (no) | 1991-06-12 |
| NO912252A NO912252A (no) | 1991-12-16 |
| NO180540B NO180540B (no) | 1997-01-27 |
| NO180540C NO180540C (no) | 1997-05-07 |
| NO180540B1 true NO180540B1 (no) | 1997-05-26 |
Family
ID=15642948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19912252A NO180540B1 (no) | 1990-06-15 | 1991-06-12 | Analogifremgangsmate for fremstilling av terapeutisk aktiv cyklisk amidderivat |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US5292735A (fr) |
| EP (3) | EP0742216B1 (fr) |
| JP (2) | JP2807577B2 (fr) |
| KR (1) | KR940004391B1 (fr) |
| CN (1) | CN1045206C (fr) |
| AT (3) | ATE170517T1 (fr) |
| AU (2) | AU653938B2 (fr) |
| CA (2) | CA2044515C (fr) |
| DE (3) | DE69130120T2 (fr) |
| DK (2) | DK0468187T3 (fr) |
| ES (2) | ES2113355T3 (fr) |
| FI (1) | FI114797B (fr) |
| HU (2) | HU216188B (fr) |
| NO (1) | NO180540B1 (fr) |
| NZ (2) | NZ238534A (fr) |
| PT (1) | PT97993B (fr) |
| ZA (1) | ZA914423B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| FR2677019B1 (fr) * | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| US5462934A (en) * | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
| KR100259107B1 (ko) * | 1992-04-23 | 2000-07-01 | 슈테펜 엘. 네스비트 | 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| ATE194982T1 (de) | 1992-04-24 | 2000-08-15 | Takeda Chemical Industries Ltd | Benzoxazepin-derivate als cholinesterase- inhibitoren |
| EP0638567A4 (fr) * | 1993-02-18 | 1995-05-10 | Kyowa Hakko Kogyo Kk | Inhibiteur de l'incorporation d'adenosine. |
| US5869499A (en) * | 1993-07-15 | 1999-02-09 | Pfizer Inc | Benzyloxyquinuclidines as substance P antagonists |
| ES2132284T3 (es) * | 1993-08-05 | 1999-08-16 | Hoechst Marion Roussel Inc | Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa. |
| FR2750991A1 (fr) * | 1996-07-12 | 1998-01-16 | Pf Medicament | Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament |
| FR2752732B1 (fr) | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| DE19708846A1 (de) * | 1997-03-05 | 1998-09-17 | Gruenenthal Gmbh | Neue Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| EP1891954A3 (fr) | 1998-09-30 | 2009-01-14 | Takeda Pharmaceutical Company Limited | Agents pour améliorer le pouvoir de vidange de la vessie |
| US7794761B2 (en) * | 2000-04-13 | 2010-09-14 | Seroctin Research & Technology, Inc. | Methods for inducing anti-anxiety and calming effects in animals and humans |
| US20040192669A1 (en) | 2000-04-13 | 2004-09-30 | Rosenfeld Mark J. | Novel compounds for use in weight loss and appetite suppression in humans |
| EP1494671B1 (fr) * | 2002-04-18 | 2011-10-19 | Schering Corporation | 1-(4-piperidinyl)benzimidazolones utilises en tant qu'antagonistes du recepteur h3 de l'histamine |
| US7524877B2 (en) | 2003-11-20 | 2009-04-28 | Seroctin Research & Technology, Inc. | Compounds for use in weight loss and appetite suppression in humans |
| GB0507695D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| CN101437510B (zh) * | 2006-03-20 | 2012-12-05 | 科学与工业研究会 | 用作乙酰胆碱酯酶抑制剂的药物组合物 |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| NO3034079T3 (fr) | 2010-11-15 | 2018-06-09 | ||
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| CA2891122C (fr) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methodes et compositions pour le traitement de la schizophrenie |
| WO2014144663A1 (fr) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Procédés et compositions pour améliorer la fonction cognitive |
| WO2014144801A1 (fr) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Procédés et compositions pour améliorer la fonction cognitive |
| CN103224498B (zh) * | 2013-05-07 | 2015-10-28 | 陈定奔 | 两种唑并喹唑啉酮稠杂环的新合成方法 |
| MX2016007808A (es) | 2013-12-20 | 2016-09-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. |
| AU2015210833B2 (en) | 2014-02-03 | 2019-01-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| JP6564029B2 (ja) | 2014-10-14 | 2019-08-21 | ヴァイティー ファーマシューティカルズ，エルエルシー | Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤 |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| EP3331876B1 (fr) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulateurs de ror-gamma |
| MX2018006223A (es) | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Moduladores de ror-gamma. |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3658555A1 (fr) | 2017-07-24 | 2020-06-03 | Vitae Pharmaceuticals, LLC | Inhibiteurs de ror |
| WO2019018975A1 (fr) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de ror gamma |
| CN108623610B (zh) * | 2018-06-04 | 2020-08-11 | 中国科学院化学研究所 | 一种氮杂*酮化合物及其制备方法 |
| WO2019246300A1 (fr) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Dérivés de benzodiazépine, compositions, et méthodes de traitement de déficience cognitive |
| CN108658887B (zh) * | 2018-06-20 | 2022-04-05 | 中南大学 | 苯并[d][1,3]噁嗪-2,4(1H)-二酮衍生物及其合成方法和用途 |
| WO2024039886A1 (fr) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3494932A (en) * | 1967-06-26 | 1970-02-10 | American Cyanamid Co | Aminoalkyl substituted aryl hydantoins |
| ZA76475B (en) * | 1975-03-10 | 1977-08-31 | Ciba Geigy Ag | Indolyalkylpiperidines |
| US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
| DE2639718A1 (de) * | 1976-09-03 | 1978-03-16 | Thomae Gmbh Dr K | Neue phenylaethylamine |
| JPS5344574A (en) * | 1976-10-01 | 1978-04-21 | Yoshitomi Pharmaceut Ind Ltd | Hydantoin derivatives |
| US4174443A (en) * | 1977-12-30 | 1979-11-13 | Gaf Corporation | Aza-bis-lactams |
| GR71865B (fr) * | 1978-03-20 | 1983-07-07 | Ciba Geigy | |
| IL57005A (en) * | 1978-04-11 | 1983-11-30 | Smith Kline French Lab | Process for the preparation of 2-amino pyrimid-4-one derivatives and novel 2-nitroaminopyrimid-4-ones as intermediates therefor |
| JPS54160371A (en) * | 1978-06-02 | 1979-12-19 | Kyowa Hakko Kogyo Co Ltd | Novel piperidine derivative and hypotensive agents comprising it |
| JPS5524155A (en) * | 1978-08-10 | 1980-02-21 | Yoshitomi Pharmaceut Ind Ltd | Piperidine derivative having heterocyclic ring at 4-position |
| US4496567A (en) * | 1978-11-13 | 1985-01-29 | Smith Kline & French Laboratories Limited | Phenyl alkylaminopyrimidones |
| JPS5576872A (en) * | 1978-12-06 | 1980-06-10 | Yoshitomi Pharmaceut Ind Ltd | Imidazolidinone derivative |
| US4521418A (en) * | 1979-02-21 | 1985-06-04 | Smith Kline & French Laboratories Limited | Guanidinothiazolyl derivatives |
| US4329348A (en) * | 1979-02-26 | 1982-05-11 | Ciba-Geigy Corporation | N-Oxacyclic-alkylpiperidines as psychostimulants |
| DE2924064A1 (de) * | 1979-06-15 | 1980-12-18 | Boehringer Sohn Ingelheim | Neue 1- eckige klammer auf n-phenylalkyl-piperidyl-(4) eckige klammer zu -imidazolidinone-(2) und verfahren zu ihrer herstellung |
| SE7907121L (sv) * | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
| JPS5924990B2 (ja) * | 1979-11-21 | 1984-06-13 | 協和醗酵工業株式会社 | 新規なピペリジン誘導体 |
| DE3066434D1 (en) * | 1979-11-21 | 1984-03-08 | Kyowa Hakko Kogyo Kk | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them |
| JPS6043064B2 (ja) * | 1979-11-28 | 1985-09-26 | ウェルファイド株式会社 | 新規イソオキサゾ−ル誘導体 |
| JPS56142280A (en) * | 1980-04-08 | 1981-11-06 | Yoshitomi Pharmaceut Ind Ltd | Piperidine compound |
| DE3026534A1 (de) * | 1980-07-12 | 1982-03-18 | C.H. Boehringer Sohn, 6507 Ingelheim | 3,1-benzoxazin-2-one, ihre herstellung und verwendung |
| JPS5753481A (en) * | 1980-09-17 | 1982-03-30 | Yoshitomi Pharmaceut Ind Ltd | 4-hydrouracil-piperidines |
| ZW21281A1 (en) * | 1980-10-01 | 1981-11-18 | Smith Kline French Lab | Amine derivatives |
| US4352933A (en) * | 1981-02-06 | 1982-10-05 | Smithkline Beckman Corporation | Chemical methods and intermediates for preparing substituted pyrimidinones |
| DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| US4490369A (en) * | 1981-05-19 | 1984-12-25 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Benzazepine derivatives, their pharmaceutical compositions and method of use |
| JPS57212180A (en) * | 1981-06-19 | 1982-12-27 | Yoshitomi Pharmaceut Ind Ltd | Tetrahydrofuran(thiophene) compound |
| US4420615A (en) * | 1981-08-24 | 1983-12-13 | Merck & Co., Inc. | Substituted pyridopyrimidines as gastric secretion inhibitors |
| IL66866A (en) * | 1982-04-09 | 1987-08-31 | Hoechst Roussel Pharma | 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them |
| ZA836995B (en) * | 1982-09-30 | 1984-05-30 | Robins Co Inc A H | Fused arpmatic oxazepinones and sulfur analogs thereof in a method of counteracting histamine |
| DE3382028D1 (de) * | 1982-09-30 | 1991-01-10 | Robins Co Inc A H | Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist. |
| US4600758A (en) * | 1982-11-12 | 1986-07-15 | Mead Johnson & Company | Isoindole derivatives |
| US4495194A (en) * | 1982-11-12 | 1985-01-22 | Mead Johnson & Company | Antihypertensive isoindole derivatives |
| JPS5995265A (ja) * | 1982-11-19 | 1984-06-01 | Yoshitomi Pharmaceut Ind Ltd | ピロリジン誘導体 |
| US4505911A (en) * | 1983-10-13 | 1985-03-19 | Mead Johnson & Company | Isoindole diuretic derivatives, compositions and use |
| JPS60169470A (ja) * | 1984-02-10 | 1985-09-02 | Chugai Pharmaceut Co Ltd | 新規なフエニルピペラジン誘導体 |
| AR241161A1 (es) * | 1984-07-30 | 1991-12-30 | Merrelll Dow Pharmaceuticals I | "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida" |
| EP0204349A3 (fr) * | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Dérivés d'amines hétéroaromatiques, médicaments les contenant et procédé pour leur préparation |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| GB8609331D0 (en) * | 1986-04-16 | 1986-05-21 | Pfizer Ltd | Anti-arrythmia agents |
| DE3631013A1 (de) * | 1986-09-12 | 1988-03-24 | Thomae Gmbh Dr K | Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE3640641A1 (de) * | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| CA1305148C (fr) * | 1987-08-19 | 1992-07-14 | Hiromu Matsumura | Derives de carbamoylpyrrolidone et produits pharmaceutiques pour la demence senile |
| EP0312283A3 (fr) * | 1987-10-14 | 1990-05-09 | Merck & Co. Inc. | Inhibiteurs de la rénine di-ou tripeptidiques, contenant une restriction conformationnelle du type lactame dans ACHPA |
| DE3738844A1 (de) * | 1987-11-16 | 1989-05-24 | Merck Patent Gmbh | Analgetikum |
| JP2699511B2 (ja) * | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| FI892362A (fi) * | 1988-06-01 | 1989-12-02 | Eisai Co Ltd | Buten- eller propensyraderivat. |
| FR2640266B2 (fr) * | 1988-07-12 | 1992-07-10 | Synthelabo | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique |
| FR2636065B1 (fr) * | 1988-09-08 | 1993-05-07 | Fabre Sa Pierre | Nouveaux derives de dihydro-2,3 arylacoylaminoalcoyl-3 4h-benzoxazine-1,3 ones-4, leur preparation et leur application en tant que medicaments utiles en therapeutique |
| US4910302A (en) * | 1988-12-19 | 1990-03-20 | American Home Products Corporation | Psychotropic polycyclic imides |
| JP2777159B2 (ja) * | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
| JPH02193992A (ja) * | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
| IL93473A0 (en) * | 1989-02-28 | 1990-11-29 | Pfizer | Antiinflammatory benzoxazolones |
| JP2747013B2 (ja) * | 1989-05-19 | 1998-05-06 | エーザイ株式会社 | ブテン酸又はプロペン酸誘導体 |
| JP2725378B2 (ja) * | 1989-05-29 | 1998-03-11 | 武田薬品工業株式会社 | カルバミド酸エステル誘導体 |
| EP0497843A4 (en) * | 1989-10-27 | 1992-09-23 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| TW197442B (fr) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| DK37790A (da) * | 1990-02-13 | 1991-08-14 | Novo Nordisk As | Indolderivater, deres fremstilling og anvendelse |
| FR2660657B1 (fr) * | 1990-04-09 | 1993-05-07 | Adir | Nouveaux derives du 3-aminochromane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| ATE174908T1 (de) * | 1993-05-26 | 1999-01-15 | Sumitomo Pharma | Chinazolinonderivate |
-
1991
- 1991-05-22 JP JP3117420A patent/JP2807577B2/ja not_active Expired - Lifetime
- 1991-06-03 AU AU78136/91A patent/AU653938B2/en not_active Expired
- 1991-06-10 KR KR91009534A patent/KR940004391B1/ko not_active IP Right Cessation
- 1991-06-10 ZA ZA914423A patent/ZA914423B/xx unknown
- 1991-06-12 NO NO19912252A patent/NO180540B1/no not_active IP Right Cessation
- 1991-06-13 AT AT95108191T patent/ATE170517T1/de not_active IP Right Cessation
- 1991-06-13 DE DE69130120T patent/DE69130120T2/de not_active Expired - Lifetime
- 1991-06-13 DE DE69129090T patent/DE69129090T2/de not_active Expired - Lifetime
- 1991-06-13 DK DK91109708T patent/DK0468187T3/da active
- 1991-06-13 EP EP96109320A patent/EP0742216B1/fr not_active Expired - Lifetime
- 1991-06-13 NZ NZ238534A patent/NZ238534A/en not_active IP Right Cessation
- 1991-06-13 AT AT96109320T patent/ATE209198T1/de not_active IP Right Cessation
- 1991-06-13 DE DE69132827T patent/DE69132827T2/de not_active Expired - Lifetime
- 1991-06-13 ES ES91109708T patent/ES2113355T3/es not_active Expired - Lifetime
- 1991-06-13 AT AT91109708T patent/ATE164156T1/de not_active IP Right Cessation
- 1991-06-13 CA CA002044515A patent/CA2044515C/fr not_active Expired - Lifetime
- 1991-06-13 FI FI912851A patent/FI114797B/fi not_active IP Right Cessation
- 1991-06-13 DK DK95108191T patent/DK0677516T3/da active
- 1991-06-13 EP EP91109708A patent/EP0468187B1/fr not_active Expired - Lifetime
- 1991-06-13 EP EP95108191A patent/EP0677516B1/fr not_active Expired - Lifetime
- 1991-06-13 CA CA002175502A patent/CA2175502C/fr not_active Expired - Lifetime
- 1991-06-13 ES ES95108191T patent/ES2123858T3/es not_active Expired - Lifetime
- 1991-06-13 NZ NZ272015A patent/NZ272015A/xx not_active IP Right Cessation
- 1991-06-14 HU HU911986A patent/HU216188B/hu unknown
- 1991-06-14 US US07/715,754 patent/US5292735A/en not_active Expired - Lifetime
- 1991-06-14 PT PT97993A patent/PT97993B/pt not_active IP Right Cessation
- 1991-06-15 CN CN91104087A patent/CN1045206C/zh not_active Expired - Lifetime
-
1993
- 1993-12-13 US US08/165,490 patent/US5504088A/en not_active Expired - Lifetime
-
1995
- 1995-01-18 AU AU10246/95A patent/AU680704B2/en not_active Expired
- 1995-05-25 US US08/449,738 patent/US5654308A/en not_active Expired - Lifetime
- 1995-05-25 US US08/451,068 patent/US5919778A/en not_active Expired - Lifetime
- 1995-05-25 US US08/449,739 patent/US5620976A/en not_active Expired - Lifetime
- 1995-05-25 US US08/449,749 patent/US5521182A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00611P patent/HU211895A9/hu unknown
- 1995-09-11 JP JP23238195A patent/JP3224187B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO180540B1 (no) | Analogifremgangsmate for fremstilling av terapeutisk aktiv cyklisk amidderivat | |
| EP0579263B1 (fr) | Pipéridines 1,4-substituées comme inhibiteurs de l'acétylcholinestérase et leur utilisation dans le traitement de la maladie d'alzheimer | |
| JP4339547B2 (ja) | １−アロイル−ピペリジニルベンズアミジン | |
| KR20100046060A (ko) | 치료적 이속사졸 화합물 | |
| US6071932A (en) | Carbazolypiperines as GABA uptake inhibitors | |
| BRPI0411713B1 (pt) | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização | |
| RU2336273C2 (ru) | Амидное производное | |
| US5447928A (en) | Benzoxazine derivatives and their application in therapy | |
| NZ243013A (en) | ((arylalkylpiperidin-4-yl)methyl)-2a,3,4,5-tetrahydro-1(2h)-acenaphthylen-1- one derivatives and pharmaceutical compositions thereof | |
| EP0497303B1 (fr) | Dérivés de l'acide carbamique et procédé pour leur préparation | |
| FR2702214A1 (fr) | Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| NO174504B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av 1,2,5,6-tetrahydropyridin-3-carboxaldehyd-oxim | |
| RU2605931C2 (ru) | Фторзамещенные циклические аминосоединения и способы их получения, фармацевтические композиции и их применения | |
| US5434179A (en) | Method for improving brain function using cholinesterase-inhibiting aminoketone compounds | |
| JP3220225B2 (ja) | グアニジノフェノール誘導体 | |
| NO179519B (no) | Analogifremgangsmåte for fremstilling av 3-(1,2-benzisoksazol-3-yl)-4-pyridinaminer og derivater derav | |
| KR20070094949A (ko) | 2-(시클릭 아미노카르보닐)인돌린 유도체 및 그것을함유하는 약제학적 조성물 | |
| JPH06306052A (ja) | キノリンまたはキナゾリン誘導体を含有する医薬組成物およびそれに用いる新規化合物 | |
| JP3113447B2 (ja) | アミノカルボン酸誘導体、その製造方法および用途 | |
| MXPA06009656A (en) | Indanol derivative | |
| JPH04120069A (ja) | トロポロン誘導体およびこれを有効成分とする虚血性疾患の予防・治療剤 | |
| KR20020042619A (ko) | 황산모노-[3-(｛1-[2-(4-플루오로-페닐)-에틸]-피페리딘-4-일｝-하이드록시-메틸)-2-메톡시-페닐]에스테르 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: JK THORSENS PATENTBUREAU AS, POSTBOKS 9276 GRONLAN |
|
| MK1K | Patent expired |